hypromelloses
Small moleculeexperimental
Hypromellose is a semisynthetic, inert, viscoelastic methyl and hydroxypropyl mixed ether of cellulose used as eye drops, as well as an excipient and controlled-delivery component in oral medicaments, found in a variety of commercial products. Hypromellose is considered an inert substance as it has no direct pharmacological activity. The viscosity promoting properties of hypromellose prolong the retention time and improve adhesion of synthetic tears to the cornea and conjunctiva. As a result, the tear film breakdown time is prolonged and/or the tear film stability is enhanced. A stable tear film protects the cornea from dryness Hypromellose is the most commonly used in hydrophilic matrix fabrication. Hypromellose provides the release of a drug in a controlled manner, effectively increasing the duration of release of a drug to prolong its therapeutic effect. — NCATS
Clinical trial activity
44 trials · 54 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
11
Phase 3
2
Phase 4
20
Earliest trial started Jul 1, 2006 (NCT00266838)
Timeline
Indications
Approved for
Studied for
- Asthenopia · Phase 4
- Cataract · Phase 4
- Conjunctivitis · Phase 4
- Conjunctivitis, Allergic · Phase 4
- Constipation · Phase 2
- Corneal Diseases · Phase 4
- Corneal Edema · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Dry Eye Syndromes · Phase 4
- Eye Diseases · Phase 1
- Eye Infections · Phase 4
- Fatty Liver · Phase 1/Phase 2
- Glaucoma · Phase 4
- Graves Ophthalmopathy · Phase 4
- Intestinal Neoplasms · Phase 2
- Intraocular Pressure · Phase 4
- Keratoconus · Phase 1/Phase 2
- Lacrimal Apparatus Diseases · Phase 1
- Liver Cirrhosis · Phase 1/Phase 2
- Macular Edema · Phase 4
- Neoplasms · Phase 1
- Non-alcoholic Fatty Liver Disease · Phase 1/Phase 2
- Ocular Hypertension · Phase 4
- Postoperative Complications · Phase 4
- Prostatic Neoplasms · Phase 4
- Retinal Diseases · Phase 2/Phase 3
- Rhinitis, Allergic · Phase 2
- Rhinitis, Allergic, Seasonal · Phase 4
- Rosacea · Phase 2
- Sprains and Strains · Phase 4
- Uveitis, Anterior · Phase 4
- Varicella Zoster Virus Infection · Phase 2
- Vision, Ocular · Phase 1
- Vitreoretinopathy, Proliferative · Phase 2/Phase 3
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS3NXW29V3WO ↗
- ChEMBLCHEMBL2108956 ↗
- NCATSZ78RG6M2N2 ↗
- NCATSRN3152OP35 ↗
- NCATS36SFW2JZ0W ↗
- NCATS273FM27VK1 ↗
Also known as
- artelac
- artelac sdu
- cellulose, 2-hydroxypropyl methyl ether
- cellulose hydroxypropyl methyl ether
- cellulose hydroxypropyl methyl ether
- chick pea extractvitamin c, l-leucine, vegetable capsule (hypromellose)
- dacriosol
- genteal
- goniosol
- goniosol
- hydroxyl-propyl-methyl cellulose
- hydroxypropylmethylcellulose
- hydroxypropylmethylcellulose
- hydroxypropylmethylcellulose
- hydroxypropylmethylcellulose
- hydroxypropyl methylcellulose
- hydroxypropyl methylcellulose
- hydroxypropyl methylcellulose 2208
- hydroxypropyl methylcellulose 2910
- hydroxypropyl methylcellulose 4000
- hydroxypropyl methylcelluloses
- hypromellose
- hypromellose
- hypromellose
- hypromellose
- hypromelloses
- isopto tears
- isopto tears
- methocel e, f, j, k
- methocel e, f, j, k
- methylcellulose, propylene glycol ether of
- moisture-eyes
- propylene glycol ether of methylcellulose
- tearisol
- tearisol
- tears naturale
- tears naturale
- ultra tears
- ultra tears
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06859476 | Phase 4 | Aug 31, 2025 | Laboratorios Sophia S.A de C.V. |
| NCT06373653 | Phase 4 | Jun 30, 2024 | Laboratorios Sophia S.A de C.V. |
| NCT05660447 | Phase 2/Phase 3 (Phase 3) | Dec 19, 2022 | Thomas Jefferson University |
| NCT05577910 | N/A | Oct 8, 2022 | Chinese University of Hong Kong |
| NCT05470868 | Phase 1 | Aug 1, 2022 | Laboratorios Sophia S.A de C.V. |
| NCT04785261 | Phase 2 | Mar 26, 2021 | China Medical University |
| NCT04541888 | Phase 3 | Sep 15, 2020 | Sun Yat-Sen University, Zhaoke (Guangzhou) Pharmaceutical Limited |
| NCT04175392 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2019 | Oakland University |
| NCT04868175 | N/A | Oct 1, 2019 | The University of Hong Kong |
| NCT04087733 | Phase 4 | Sep 1, 2019 | A.O. Ospedale Maggiore di Lodi, Clinica Mediterranea, D'Annunzio University of Chieti–Pescara, Government of Italy, Ospedale Oftalmico, Torino, OSPEDALE POLICLINICO G.B. ROSSI, S.Eugenio Hospital, University of Bologna, University of Florence, University of Genoa, University of Molise, University of Pavia, University of Pisa, University of Roma La Sapienza |
| NCT03676335 | Phase 2 | May 9, 2018 | Lee's Pharmaceutical, Sun Yat-Sen University |
| NCT02533154 | Phase 4 | Sep 1, 2017 | University of Vienna |
| NCT02992392 | N/A | Dec 1, 2016 | Sun Yat-Sen University |
| NCT02817191 | N/A | Jun 1, 2016 | Sun Yat-Sen University |
| NCT04020705 | N/A | Sep 22, 2015 | Istituto di Ricerca Neuroftalmologia S.r.l., University of Milan |
| NCT02423564 | Phase 2 | May 1, 2015 | KGK Science Inc. |
| NCT02557269 | Phase 4 | May 1, 2015 | Association Asthma, Bulgaria, Medical University of Sofia, Nasaleze |
| NCT02382588 | Phase 2 | Jan 1, 2015 | Bausch & Lomb, Northwestern University |
| NCT02308501 | Phase 4 | Dec 1, 2014 | ORA, Inc. |
| NCT02059655 | Phase 4 | Nov 1, 2014 | Cardiff University |
Showing 20 of 44 trials
Page 1 / 3
Organizations
Research & Development (54)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 4 | 4 | 1 | 2009 |
| ORA, Inc. | For profit | 4 | 4 | 2 | 2009 |
| Sun Yat-Sen University | Academic/Hospital | 4 | 2 | 3 | 2016 |
| Laboratorios Sophia S.A de C.V. | For profit | 3 | 3 | 2 | 2022 |
| Association Asthma, Bulgaria | Academic/Hospital | 2 | 2 | 2 | 2013 |
| Nasaleze | For profit | 2 | 0 | 2 | 2013 |
| Novartis | For profit | 2 | 1 | 1 | 2007 |
| University of Campinas | Academic/Hospital | 2 | 2 | 1 | 2011 |
| Aciex Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2011 |
| A.O. Ospedale Maggiore di Lodi | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Augusta University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Bausch & Lomb | For profit | 1 | 0 | 1 | 2015 |
| Bp Consulting, Inc | For profit | 1 | 1 | 1 | 2008 |
| Cardiff University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Catholic University of Korea | Academic/Hospital | 1 | 1 | 1 | 2011 |
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Chinese University of Hong Kong | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Clinica Mediterranea | Academic/Hospital | 1 | 0 | 1 | 2019 |
| D'Annunzio University of Chieti–Pescara | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2013 |
54 organizations
Page 1 / 3